Date / Time
The goal of this activity is to improve the knowledge and competence of learners to integrate new and emerging therapies into the treatment of patients with relapsed/refractory multiple myeloma.
This program is intended for global hematologists, medical oncologists, and other healthcare providers who care for patients with MM.
Upon completion of this activity, participants should be able to:
- Describe the efficacy and safety evidence of novel combination therapeutic regimens for R/R MM
- Explain the mechanism of action of newer classes of agents indicated for and under investigation for R/R MM
- Select optimal therapies for patients with heavily pretreated R/R MM based on individual patient and disease characteristics
- Manage toxicities with newer agents and combination regimens in patients with heavily pretreated R/R MM
- Identify patients with R/R MM who would be eligible for enrollment in late-phase clinical trials
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.